KLC1: Kinesin Light Chain 1
A key component of the kinesin-1 motor complex involved in intracellular transport, neuronal function, and implicated in cancer and neurodegenerative disorders.
Gene Information Card
| Symbol | KLC1 |
|---|---|
| Full Name | kinesin light chain 1 |
| Gene Type | protein coding |
| Chromosomal Location | 14q32.33 |
| NCBI Gene ID | 3831 ncbi.nlm.nih.gov/gene/3831 |
| Ensembl ID | ENSG00000100811 |
| UniProt ID | Q07866 |
| OMIM ID | 600540 |
| HGNC ID | 6386 |
| Aliases | KNS2, KLC, KLC1A, KLC1B, KLC1C, KLC1D |
Description
KLC1 (kinesin light chain 1) encodes a member of the kinesin light chain family. The encoded protein is a light chain of kinesin-1, a microtubule-associated motor complex that transports cargoes such as vesicles, organelles, and protein complexes along microtubules toward the plus end. KLC1 interacts with kinesin heavy chain (KIF5) and various cargo adaptors, playing critical roles in neuronal transport, cell division, and intracellular signaling. Alternative splicing generates multiple isoforms with distinct cargo-binding properties.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hereditary spastic paraplegia (HSP) | Loss-of-function mutations in KLC1 impair axonal transport of synaptic cargoes, leading to progressive corticospinal tract degeneration. | OMIM #600540; PMID: 32891193 |
| Breast cancer | KLC1 overexpression and fusion events (e.g., KLC1-ALK) promote oncogenic signaling and cell proliferation. | COSMIC; PMID: 25670082 |
| Lung adenocarcinoma | KLC1-ALK fusion gene acts as a driver mutation, constitutively activating ALK kinase and downstream pathways. | COSMIC; PMID: 25670082 |
| Alzheimer's disease | KLC1 dysfunction disrupts amyloid precursor protein (APP) transport, contributing to amyloid-beta accumulation. | PMID: 22956769 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 38.5 | High |
| Testis | 22.1 | Medium |
| Lung | 15.3 | Medium |
| Liver | 8.7 | Low |
| Heart | 12.4 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| SH-SY5Y (neuroblastoma) | 45.2 | High expression; neuronal model |
| HeLa (cervical carcinoma) | 28.6 | Moderate expression |
| A549 (lung carcinoma) | 19.8 | Moderate expression |
| HEK293 (embryonic kidney) | 35.1 | High expression; common for recombinant studies |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1045C>T (p.Arg349*) | Nonsense | Rare | Loss of function; truncation of C-terminal cargo-binding domain |
| c.154G>A (p.Gly52Arg) | Missense | Rare | Impaired kinesin heavy chain binding; reduced transport |
| KLC1-ALK fusion | Gene fusion | 0.5-1% in NSCLC | Constitutive ALK activation; oncogenic driver |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations (e.g., p.Arg349*) truncate the protein, disrupting cargo binding and axonal transport, leading to hereditary spastic paraplegia.
Gain of Function (GOF)
KLC1-ALK fusions result in constitutive ALK kinase activity, driving oncogenic signaling in lung adenocarcinoma and other cancers.
Dominant Negative (DN)
Missense mutations in the heptad repeat region (e.g., p.Gly52Arg) produce a defective light chain that interferes with wild-type kinesin-1 complex assembly, impairing transport.
View complete mutation data:
Gene Ontology (GO)
Pathways
• Kinesin-mediated transport (Reactome: R-HSA-983189)
• Axonal transport (Reactome: R-HSA-983189)
• Vesicle-mediated transport (Reactome: R-HSA-5653656)
• ALK signaling in cancer (KEGG: hsa05223)
Protein Summary
KLC1 (kinesin light chain 1) is a 569-amino acid protein (UniProt Q07866) that forms the light chain component of the kinesin-1 heterotetramer (two heavy chains, two light chains). It contains N-terminal heptad repeats for heavy chain binding and C-terminal tetratricopeptide repeat (TPR) domains for cargo recognition. KLC1 mediates the transport of vesicles, mitochondria, and protein complexes along microtubules. Alternative splicing generates isoforms with tissue-specific cargo selectivity. Post-translational modifications (e.g., phosphorylation) regulate its interaction with adaptors such as JIP1 and APP. Dysfunction is linked to neurodegenerative diseases and cancer.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| KLC1 Knockout HEK293 Cell Line | EDJ-KQ50407 | Human | 3831 | Details Get a Quote |
| KLC1 Knockout HeLa Cell Line | EDJ-KQ53749 | Human | 3831 | Details Get a Quote |
| KLC1 Knockout A-549 Cell Line | EDJ-KQ62226 | Human | 3831 | Details Get a Quote |
| KLC1 Knockout HCT 116 Cell Line | EDJ-KQ70710 | Human | 3831 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records